Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.4K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.4K
Antimicrobial Proteins01:23

Antimicrobial Proteins

15.2K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
15.2K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.8K
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

2.0K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
2.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden.

Advanced healthcare materials·2026
Same author

Correction: VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study.

Frontiers in immunology·2026
Same author

A Sequence-Based Update on Amino Acid Substitutions in Influenza Polymerase Acidic Protein in Europe That Alter Baloxavir Susceptibility From 2009 to 2025.

Influenza and other respiratory viruses·2026
Same author

Optimized lentiviral vectors a solution for paediatric metabolic liver diseases.

Journal of hepatology·2026
Same author

Locus coeruleus α-synuclein overexpression induces prodromal Parkinsonian features in mice.

NPJ Parkinson's disease·2026
Same author

VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study.

Frontiers in immunology·2026

Related Experiment Video

Updated: Mar 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function.

Marcos Vasquez1, Jessica Fioravanti1, Fernando Aranda1

  • 1Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Navarra Institute for Health Research (IdiSNA) , Pamplona, Navarra, Spain.

Oncoimmunology
|September 14, 2016
PubMed
Summary

Scavenger receptor class B type I (SR-B1) ligands boost interferon-alpha (IFNα) antiviral and antitumor effects by activating TLR2/4. SR-B1 inhibition blocks IFNα signaling, offering new cancer immunotherapy targets.

Keywords:
Adeno-associated virusNewcastle disease virusToll-like receptorcolorectal cancerliver metastases

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

12.6K

Related Experiment Videos

Last Updated: Mar 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.6K
A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
11:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

12.6K

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Scavenger receptor class B type I (SR-B1) is known to bind pathogen-associated molecular patterns involved in inflammation.
  • The interaction between SR-B1 and the interferon system, particularly interferon-alpha (IFNα), has not been previously elucidated.

Purpose of the Study:

  • To investigate the role of SR-B1 in regulating IFNα's biological activity.
  • To explore the potential of targeting SR-B1 for enhancing cancer immunotherapy strategies.

Main Methods:

  • Treatment of cells with SR-B1 ligands and assessment of transcriptional response to IFNα.
  • Use of blocking antibodies against Toll-like receptor 2 (TLR2) and TLR4 to determine the mechanism of action.
  • In vivo studies using adeno-associated viruses for co-expression of SR-B1 ligands and IFNα in a liver cancer model.
  • Genetic and pharmacological inhibition of SR-B1 to evaluate its impact on IFNα signaling and receptor recycling.
  • Assessment of SR-B1 antagonists in combination with oncolytic viruses for cancer treatment.

Main Results:

  • SR-B1 ligands significantly enhance the transcriptional response to IFNα, boosting its antiviral and antitumor activities.
  • The observed effects are mediated by the activation of TLR2 and TLR4, as confirmed by blocking antibody experiments.
  • In vivo gene therapy with SR-B1 ligands and IFNα eradicated liver metastases from colon cancer with reduced toxicity.
  • Inhibition of SR-B1 disrupts clathrin-dependent interferon receptor recycling, diminishing IFNα signaling and bioactivity.
  • SR-B1 antagonists promote oncolytic virus replication, increasing their tumoricidal potential.

Conclusions:

  • SR-B1 agonists act as potent enhancers of IFNα activity, while SR-B1 inhibitors dampen it.
  • SR-B1 represents a promising pharmacological target for augmenting cancer immunotherapy, particularly when combined with IFNα or oncolytic viruses.